On 13 June, in a meeting facilitated by the EUnetHTA Directorate and supported by DG SANTE, European stakeholders of Health Technology Assessments (focus pharmaceuticals) came together to discuss important new developments for further cooperation.
A new joint platform for parallel consultation will provide advice to medicine developers and facilitate access to medicines for patients
We are pleased to announce that the collaborative rapid assessment of JA3 WP4 on “ANTIBACTERIAL-COATED SUTURES VERSUS NON-ANTIBACTERIAL-COATED SUTURES FOR THE PREVENTION OF ABDOMINAL, SUPERFICIAL AND DEEP INCISIONAL, SURGICAL SITE INFECTION (SSI)” is available.
We are pleased to announce that the CA of JA3 WP4 on “Repetitive transcranial magnetic stimulation for treatment-resistant major depression” is available.
A call for Expression of Interest to participate in EUnetHTA JA3 Early Dialogues has now been published.